Continuous 6-h infusions of the beta adrenergic blockers d,l-propranolol or oxprenolol significantly reduced plasma renin activity (PRA) and mean blood pressure in the resting rabbit and prevented the stimulatory effects of isoproterenol on renin release and heart rate. These actions were due to blockade of beta receptors, for the inactive isomer, d-propranolol, had no effect. Despite sustained high plasma concentrations of d,l-propranolol (0.2 µg/ml) in the unstimulated animal, PRA did not fall below 36% of control values, suggesting that basal renin secretion is maintained partly by factors other than beta adrenergic mechanisms.
A B S T R A C T Continuous 6-h infusions of the beta adrenergic blockers dl-propranolol or oxprenolol significantly reduced plasma renin activity (PRA) and mean blood pressure in the resting rabbit and prevented the stimulatory effects of isoproterenol on renin release and heart rate. These actions were due to blockade of beta receptors, for the inactive isomer, d-propranolol, had no effect. Despite sustained high plasma concentrations of dl-propranolol (0.2 Ag/ml) in the unstimulated animal, PRA did not fall below 36% of control values, suggesting that basal renin secretion is maintained partly by factors other than beta adrenergic mechanisms.
Prindolol, another beta blocker, also abolished the effects of isoproterenol on renin and on the heart, and reduced blood pressure in the resting animal. However, prindolol increased resting PRA and heart rate, and in animals already receiving dl-propranolol, it raised PRA and heart rate without further altering blood pressure. This suggests that the effect on PRA of prindolol was due to its intrinsic sympathomimetic activity and not hypotension-mediated mechanisms. The observation that the blood pressure-lowering effect of prindolol was associated with a rise in PRA, while another beta antagonist, H 35/25, lowered PRA but had no effect on blood pressure, indicates that the hypotensive action of beta blockers is unrelated to their effects on renin release.
In both unstimulated and isoproterenol-challenged animals, only blockers possessing beta-i receptor affinity (d,t-propranolol, oxprenolol, prindolol, practolol, and metoprolol) affected heart rate, while effects on PRA were more prominent with agents possessing beta-2 activity (dl-propranolol, oxprenolol, prindolol, and H 35/25). Thus, the changes in PRA caused by the beta adrenergic blockers appear to be dependent upon the summation of their direct effects, antagonistic or sympathomimetic, on beta-2 adrenergic receptors regulating renin release.
INTRODUCTION
Sympathetic mechanisms are known to have a role in the regulation of renin release. Renin secretion is increased by renal nerve stimulation (1) and by either intravenous administration or endogenous stimulation of catecholamines (1, 2) . These stimuli appear to be mediated by beta adrenergic receptors, for the stimulatory effect on renin release of catecholamines (3), isoproterenol (4), or medulla oblongata stimulation (5) is prevented by the beta blocker propranolol, but not the alpha blocker phenoxybenzamine.
We have recently reported that single doses of d,lpropranolol or oxprenolol produced an acute fall in plasma renin activity (PRA) ,' but prindolol, a beta blocker with sympathomimetic actvity, increased PRA (6). It was not clear whether these effects of beta antagonists on renin were direct or dependent upon reflex mechanisms activated by changes in blood pressure.
To clarify the mechanism of action of beta blocking agents on the renin-angiotensin system, we studied in the rabbit the effects on PRA, blood pressure, and heart rate of infusions of several such agents, given separately, during both resting conditions, and graded isoproterenol challenges. In further experiments, propranolol and prindolol were given concurrently to dissociate their direct effects on PRA from those secondary to changes in blood pressure. Also, an attempt was made to elucidate the specificity of the receptors regulating renin release.
METHODS
Animals. Using local anesthesia alone, arterial and venous catheters were inserted into the ear of male New Zealand white rabbits, weighing 2.2-3.3 kg, as described previously (6) . After a 90-min recovery period, the experiments were carried out in a quiet room in which external stimuli were minimized.
Infusion studies (series A). In a control group of four animals (group Al), 2.5% dextrose in water was infused 1Abbreviations used in this paper: HR, heart rate; MBP, mean blood pressure; PRA, plasma renin activity. Techniques. PRA was measured in arterial blood samples collected by free flow into glass tubes containing EDTA placed in a crushed ice bath. A radioimmunoassay method (7) was employed, angiotensin I being generated by plasma incubation at 37'C for 3 h at pH 7.4 in the presence of angiotensinase inhibitors (dimercaprol and 8-OH-quinoline). Results were expressed in nanograms angiotensin I/ml/h.
The possibility that the presence of beta blocking drugs in the plasma may have affected the generation or measurement of angiotensin I was excluded as follows: six untreated rabbit plasma samples were each divided into 3 aliquots. Aliquot 1 of each sample was a control; to aliquot samples, 11.01t.0 (SE) ng/ml, and the prindolol samples, 10 .7±1.0 (SE) ng/ml.
To prevent the increase in PRA caused by minor hemorrhage in the rabbit (8), each 1 ml of blood sampled for biochemical analysis during the experiments was replaced immediately by 0.6 ml of a protein-saline mixture composed of 25 g stable human plasma protein (86% albumin, 14% globulin) in 500 ml buffered physiological saline containing 4-6 meq/liter potassium (Commonwealth Serum Laboratories, Melbourne, Australia).
Plasma propranolol concentrations were measured in the six animals in group A2 by a spectrofluorimetric method (9) after extraction of the propranolol from plasma by n-heptane. Plasma prindolol levels were measured in the six animals in group A4 by the fluorimetric method of Pacha (10) in which the fluorescent intensity of the prindolol, extracted from plasma by diethyl ether, is enhanced by ortho-phthalaldehyde.
Plasma sodium and potassium concentrations were measured by flame photometry, and plasma glucose levels were measured by a Technicon AutoAnalyzer (Technicon Instruments Corp., Tarrytown, N. Y.) using the potassium ferricyanide method of Hoffman (11) . Packed 
RESULTS
Infusion studies (series A). In the control group (group Al), continuous infusion of 2.5% dextrose in water did not change PRA or heart rate (HR). There was a small, but not significant, fall in mean blood pressure (MBP) during the 360-min experimental period (Table II) .
The effects of infusing various beta adrenergic blocking drugs into the normal resting animal are shown in Fig. 1 . Administration of dl-propranolol (group A2) resulted in a fall in PRA from 14.1 to 5.1 ng/ml was the reduction not significant in relation to the PRA values observed in the control group (group Al).
In group A9 (Fig. 2) , PRA fell from 9.8 to 3.5 ng/ ml (P < 0.001) during infusion of dl-propranolol alone, but reverted to the control level when dl-propranolol and prindolol were infused simultaneously. Mean HR also fell during dl-propranolol administration (P < 0.001) but returned to control during the combined treatment. MBP, which fell during the propranolol infusion, was not further influenced by prindolol.
Plasma sodium, potassium, and glucose concentrations, measured at the beginning and end of each experiment in groups A1-A8, did not alter significantly. Blood packed cell volumes fell uniformly in each of the groups by a mean of 5% (P < 0.005). Plasma concentrations of propranolol and prindolol, measured in groups A2 and A4 at intervals after the first 30 min of infusion, did not vary significantly during the 360-min infusions.
Plasma concentration of propranolol was between 186±-17 (SE) and 203±17 (SE) ng/ml and that of prindolol was between 44±12 (SE) and 61±12 (SE) ng/ml.
Isoproterenol challenge studies (series B) (Fig. 3) . In a control group of six animals (group Bi), 30-min infusions of isoproterenol (0.004, 0.01, or 0.04 Ig/kg/ min) caused significant increases in PRA of 4.3+0.5 (SE), 11.0±1.6, and 18.8±2.9 ng/ml, respectively (P < 0.001). Similarly, there were significant rises in HR of 11±2 (P<0.005), 24±4 (P<0.001), and 44±4 (P <0.001)/min. and HR rose only during the high dose of isoproterenol (P <0.01). In group B5 (oxprenolol), PRA rose slightly during the high dose (P < 0.05) but HR rose during both the medium (P < 0.02) and high (P < 0.005) doses. In group B6 (H 35/25), PRA rose only during the high dose of isoproterenol (P <0.01) but there were pronounced increases in HR during the low (P <0.01), medium (P <0.001), and high (P < 0.001) dose infusions. In groups B7 (metoprolol) and B8 (practolol) there were highly significant increases in PRA, greater than those observed with the other blockers, after each of the isoproterenol challenges. HR rose only with the high dose challenge in group B7 (P <0.01) and with the medium (P<0.05) and high (P < 0.01) doses in B8. There were no significant changes in MBP caused by isoproterenol in the doses used in either the control or the treatment groups.
Plasma sodium, potassium, and glucose concentrations were measured immediately before the beginning and the end of the 30-min isoproterenol 0.04 ,.tg/kg/ min infusions (Table III) . There were no significant changes in plasma sodium concentrations in any of the groups. Plasma potassium fell in animals infused with isoproterenol alone (group B1) (P < 0.005), and in those also receiving d-propranolol (P <0.01), metoprolol (P < 0.05), or practolol (P < 0.02) but there were no changes in the other groups. Plasma potassium concentration was also reduced (P < 0.02) by infusion of isoproterenol 0.01 Ag/kg/min; the influence of the beta adrenergic blockers upon this action was not studied. The low dose isoproterenol challenge caused no significant change in plasma potassium. Plasma glucose levels rose in the 0.04 ,gg/kg/min isoproterenol control animals (group B1) (P < 0.01) and also in those receiving d-propranolol (P < 0.02) and H 35/25 (P <0.05).
DISCUSSION
It is well established that propranolol prevents the rise in renin secretion caused by experimental adrenergic stimuli (3, 5, 12) and lowers PRA in hypertensive patients (13) (14) (15) . In the present study, it was shown that oxprenolol, like d,l-propranolol, could prevent the rise in PRA caused by the beta adrenergic agonist, isoproterenol. Further, it was demonstrated that in the unstimulated rabbit, constant infusion of either propranolol or oxprenolol produced a sustained fall in PRA.
Prindolol markedly diminished the stimulatory effects of isoproterenol on the heart and on renin release, but in the resting animal, in which it had a strong hypotensive effect, prindolol caused significant rises in PRA and HR. However, when this agent was given Table I ; values given are mean±SEM, n = 6. * 0.04 gg/kg/min.
$ meq/liter. § meq/liter. mg/100 ml.
to animals already receiving propranolol, these increases occurred in the absence of changes in blood pressure. Thus, the hypereninemic and chronotropic effects of prindolol are probably direct and not dependent upon reflex mechanisms initiated by hypotension. The observation that prindolol stimulates beta adrenergic receptors in the resting animal, while preventing the agonist effects of isoproterenol, is consistent with its known intrinsic sympathomimetic properties (16) . Although beta blockers possess quinidine-like or local anesthetic properties (17) , their effects on PRA appear to be due to their actions on beta adrenergic receptors. D-Propranolol, which has the quinidine-like but not the beta antagonist properties of d,l-propranolol, failed to prevent the increase in PRA caused by isoproterenol, a finding which is in agreement with studies in the isolated kidney (18) and in man (19) .
The results in the unstimulated animal indicate that beta adrenergic receptors also have a role in sustaining resting levels of PRA. However, during the 6-h infusions of dl-propranolol, a blocker which is devoid of intrinsic sympathomimetic properties (16) , plasma renin, which has a circulating half-life of only 10-30 min (20, 21) , was not reduced below 36% control. Thus, despite sustained blood levels of propranolol considerably greater than those required for effective beta blockade (22, 23) , some renin release still occurred. This suggests that basal renin secretion is maintained, in part, by nonadrenergic mechanisms.
The beta adrenergic receptors, as defined by Ahlquist (24) , have been classified as two types: beta-1, which includes receptors mediating cardiac stimulation and lipolysis, and beta-2, including receptors situated in the Beta Adrenergic Antagonists and Renin pulmonary bronchi and in the peripheral vasculature (25) . In the doses used in the present study, the nonspecific beta blockers, propranolol, oxprenolol, and prindolol, which have affinity for both beta-1 and beta-2 receptors, abolished the increases in PRA and HR caused by all but the highest doses of isoproterenol.
H 35/25, a beta-2-specific antagonist (26) also inhibited renin release in both the resting and the isoproterenol-challenged animals, but did not inhibit the chronotropic effect of isoproterenol. Conversely, practolol and metoprolol, blockers with predominantly beta-i receptor affinity (27, 28) , inhibited the chronotropic action of isoproterenol without preventing its stimulatory effect on PRA. In the resting animal, practolol had little effect on PRA, a result which is similar to findings with beta-1 blockers in man (29, 30) . Metoprolol caused a larger reduction in PRA, but this agent possesses a lesser degree of beta-i specificity than practolol (28) and its effect on renin release could have reflected partial blockade of beta-2 receptors. These data are consistent with the concept that the action of the beta adrenergic blockers on HR is related to their beta-1 receptor activity whereas their effects on PRA depend upon their affinity for beta-2 receptors (30).
The difference between the two classes of beta receptors was emphasized by the differing metabolic effects of the blockers. The known hypokalemic action of isoproterenol (31) was prevented only by antagonists possessing beta-2 receptor affinity, whereas the hyperglycemia which is caused by isoproterenol (32), was blocked only by agents with beta-i receptor activity.
A fall in plasma potassium concentration may stimulate renin release (33, 34 (6, 35, 36) . The doses of metoprolol and H 35/25 were based on those used in studies in which their antagonism to chronotropic stimuli of the heart was compared with that of propranolol (28, 37) . We were not able to measure the plasma concentrations of all the beta blockers used because of methodological difficulties. However, plasma levels of propranolol and prindolol, which are readily assayed by spectrofluorimetric methods, were measured at intervals during the 6-h infusions in the resting animal and were shown not to vary significantly during the experiments. Thus, at least as far as these two agents were concerned, constant blood levels were achieved by the method of administration used in these studies.
Because of the suspected participation of the reninangiotensin system in the development of certain types of clinical and experimental hypertension (38, 39) , it has been suggested that the antihypertensive activity of propranolol may depend upon its PRA-lowering properties (40) . Further, in a recent study in hypertensive patients, it was concluded by Biihler et al. (41) that the antihypertensive action of propranolol involves a fall in renin secretion associated with a reduction in renin-induced vasoconstriction. However, such a mechanism does not appear to apply to the beta blockers as a class, for in the present study, H 35/25 reduced PRA without affecting blood pressure, while prindolol lowered blood pressure but increased PRA. Moreover, in previously reported work (42) we showed that when prindolol was substituted for propranolol in the treatment of hypertensive patients, blood pressure remained low despite a significant rise in PRA.
